Latest news and press releases about Revelation Biosciences, Inc. (REVB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system.
Price
| Price | $0.92 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.35 |
| EV / EBITDA | 0.62 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -100.20% |
| Return on Invested Capital | -104.28% |
| Return on Assets | -86.02% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATXI · AZTR · GTBP · INDP · NKGN · ONCO · PBM
Explore sector: Healthcare · Biotechnology
More sections of REVB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks